Pfizer Inc.

NYSE:PFE Stok Raporu

Piyasa değeri: US$143.7b

Pfizer Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Pfizer 'in gelir ve kazançlarının sırasıyla yıllık 3.7% ve 1% oranında düşmesi öngörülüyor. EPS'nin yıllık 2.6% oranında düşüşmesi bekleniyor. Öz sermaye getirisinin 3 yıl içinde 15% olması öngörülüyor.

Anahtar bilgiler

-1.0%

Kazanç büyüme oranı

-2.55%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi14.8%
Gelir büyüme oranı-3.7%
Gelecekteki özkaynak getirisi14.99%
Analist kapsamı

Good

Son güncelleme18 Jun 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Jun 20

Pfizer (PFE) Stock Could Be 10% Undervalued After CFO Exit Raises Execution Questions

Pfizer (PFE) is back in focus after the company said Chief Financial Officer Dave Denton will leave in August, with long-time finance executive Cecile Guegan stepping in as interim CFO during the search for a successor. See our latest analysis for Pfizer. The CFO announcement comes as Pfizer shares trade at US$25.21, with the stock down over the past quarter but posting a 12.52% total shareholder return over the last year. This suggests that shorter term momentum has cooled even as income and...
Seeking Alpha • Jun 17

Pfizer: Why I'm Still Expecting A Massive Rebound

Summary Pfizer Inc. remains a Buy with 55%+ upside potential over two years, driven by a robust pipeline and undervalued forward earnings. PFE's Q1 2026 results beat estimates, with non-COVID sales up 7% YoY and strong contributions from Seagen and new product launches. Key catalysts include the potential blockbuster GLP-1 candidate berobenatide, aggressive oncology growth, and patent settlements extending revenue streams. Dividend safety is high, with yields projected above 6.7% through 2028, providing downside buffer amid LOE and pipeline execution risks. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 08

PFE: Oncology And Obesity Pipeline Will Support Post Patent Cliff Repricing

Narrative update Pfizer's analyst price targets have inched higher, with a recent move such as Wolfe Research lifting its view to $26 from $25 as analysts factor in elements like the five-year sales outlook and extended Vyndamax exclusivity, while also accounting for COVID-related uncertainty in their updated assumptions. Analyst Commentary Recent Street commentary on Pfizer centers on two themes investors should keep in mind: how analysts are framing post COVID revenue visibility and how legal and partnership developments may affect long term cash flow and valuation support.
Anlatı Güncellemesi • May 25

PFE: Obesity And Oncology Pipeline Progress Will Drive Long-Term Upside Potential

Analysts have nudged Pfizer's implied fair value slightly higher to about $29.19 per share, reflecting a series of mostly modest price target increases, including Wolfe Research's move to $26. This comes alongside updated views on long term sales, COVID uncertainty, patent settlements around Vyndamax, and the recent Veppanu licensing, as well as GLP-1 and oncology pipeline commentary.
Anlatı Güncellemesi • May 03

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook

Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.
Anlatı Güncellemesi • Apr 19

PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing

Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.
Anlatı Güncellemesi • Apr 05

PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating

Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.
Anlatı Güncellemesi • Mar 22

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook

Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.
Anlatı Güncellemesi • Mar 08

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade

Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.
Anlatı Güncellemesi • Feb 21

PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating

Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.
Anlatı Güncellemesi • Feb 07

PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating

Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.
Anlatı Güncellemesi • Jan 24

PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares

Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.
Anlatı Güncellemesi • Jan 10

PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential

Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.
Analiz Makalesi • Jan 08

Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43

Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...
Anlatı Güncellemesi • Dec 25

PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead

Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.
Analiz Makalesi • Dec 18

Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...
Anlatı Güncellemesi • Dec 11

PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating

Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.
Anlatı Güncellemesi • Nov 13

PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts

Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.
Analiz Makalesi • Aug 12

Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...

Kazanç ve Gelir Büyüme Tahminleri

NYSE:PFE - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202855,3369,62915,97717,23022
12/31/202759,32310,96017,64017,91826
12/31/202661,69011,07019,52318,86526
3/29/202663,3157,4799,48311,984N/A
12/31/202562,5797,7469,07511,704N/A
9/28/202562,7859,79710,37613,077N/A
6/29/202563,83310,72812,43815,188N/A
3/30/202562,4647,86711,22013,989N/A
12/31/202463,6278,0209,83512,744N/A
9/29/202460,4334,2748,22711,263N/A
6/30/202456,223-2,5934,8108,005N/A
3/31/202455,946-2885,1068,578N/A
12/31/202359,5542,1344,7938,700N/A
10/1/202369,27410,4698,17812,042N/A
7/2/202378,42021,49410,66514,560N/A
4/2/202393,15429,03520,20623,938N/A
12/31/2022101,17531,36626,03129,267N/A
10/2/202299,87829,95323,36226,599N/A
7/3/2022101,27529,48128,44031,454N/A
4/3/202292,43325,41031,78334,583N/A
12/31/202181,28822,41329,86932,580N/A
10/3/202168,87719,48529,76932,291N/A
7/4/202155,11912,23621,14123,552N/A
4/4/202146,0849,03213,47715,808N/A
12/31/202041,6516,63012,17714,403N/A
9/27/202032,33421210,51212,547N/A
6/28/202034,7376,97712,77714,967N/A
3/29/202038,1379,42711,70214,023N/A
12/31/201940,90510,707N/A12,588N/A
9/29/201953,03916,211N/A13,557N/A
6/30/201953,65612,638N/A14,306N/A
3/31/201953,85911,464N/A15,542N/A
12/31/201840,8253,824N/A15,827N/A
9/30/201853,37323,808N/A18,178N/A
7/1/201853,24422,545N/A17,808N/A
4/1/201852,67321,746N/A17,201N/A
12/31/201752,54621,305N/A16,802N/A
10/1/201752,4719,791N/A15,463N/A
7/2/201752,3478,308N/A15,311N/A
4/2/201752,5987,281N/A15,677N/A
12/31/201652,8247,198N/A16,192N/A
10/2/201653,2436,270N/A15,049N/A
7/3/201652,2867,036N/A15,332N/A
4/3/201650,9927,615N/A15,816N/A
12/31/201548,8516,948N/A14,688N/A
9/27/201547,9228,366N/A15,188N/A
6/28/201548,1968,913N/A14,631N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PFE şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -1% ).

Kazançlar ve Piyasa: PFE şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -1% ).

Yüksek Büyüme Kazançları: PFE şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor.

Gelir ve Pazar: PFE şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -3.7% ).

Yüksek Büyüme Geliri: PFE şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -3.7% ).

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PFE 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/06/21 15:39
Gün Sonu Hisse Fiyatı2026/06/18 00:00
Kazançlar2026/03/29
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Pfizer Inc. 44 Bu analistlerden 26, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
David ToungArgus Research Company
Emily FieldBarclays
Kerry HolfordBerenberg